The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.
 
Ryan Dittamore
Employment - Epic Sciences
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - Patents Pending
 
Yipeng Wang
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Stephanie Daignault-Newton
Consulting or Advisory Role - Augmenix
Research Funding - Bayer
 
Walter Michael Stadler
Honoraria - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech
Other Relationship - American Cancer Society; UpToDate
 
Adam Jendrisak
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Research Funding - Epic Sciences
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; Dendreon; EMD Serono; Ferring; GenomeDx; Janssen Oncology; Medivation/Astellas; Sanofi
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Angel E Dago
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Jerry Lee
No Relationships to Disclose
 
Ryon P Graf
No Relationships to Disclose
 
Mark Andrew Landers
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Arul Chinnaiyan
Consulting or Advisory Role - Tempus
 
Maha Hussain
Honoraria - Onclive; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Sanofi